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Abstract
Objective. To develop evidence-based recommendations for pain management by pharmacotherapy in
patients with inflammatory arthritis (IA).
Methods. A total of 453 rheumatologists from 17 countries participated in the 2010 3e (Evidence,
Expertise, Exchange) Initiative. Using a formal voting process, 89 rheumatologists representing all
17 countries selected 10 clinical questions regarding the use of pain medications in IA. Bibliographic
fellows undertook a systematic literature review for each question, using MEDLINE, EMBASE, Cochrane
CENTRAL and 200809 European League Against Rheumatism (EULAR)/ACR abstracts. Relevant studies
were retrieved for data extraction and quality assessment. Rheumatologists from each country used this
evidence to develop a set of national recommendations. Multinational recommendations were then for-
mulated and assessed for agreement and the potential impact on clinical practice.
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Results. A total of 49 242 references were identified, from which 167 studies were included in the sys-
tematic reviews. One clinical question regarding different comorbidities was divided into two separate
reviews, resulting in 11 recommendations in total. Oxford levels of evidence were applied to each rec-
ommendation. The recommendations related to the efficacy and safety of various analgesic medications,
pain measurement scales and pain management in the pre-conception period, pregnancy and lactation.
Finally, an algorithm for the pharmacological management of pain in IA was developed. Twenty per cent of
rheumatologists reported that the algorithm would change their practice, and 75% felt the algorithm was
in accordance with their current practice.
Conclusions. Eleven evidence-based recommendations on the management of pain by pharmacotherapy
in IA were developed. They are supported by a large panel of rheumatologists from 17 countries, thus
enhancing their utility in clinical practice.
Key words: arthritis, evidence-based medicine, analgesics.
Introduction
Inflammatory arthritis (IA) affects up to 3% of the popula-
tion [1] and is characterized by pain, stiffness, loss of
function and impaired quality of life. Despite recent
advances in the management of IA, pain remains a
common experience for IA patients, who report pain man-
agement to be their highest priority [24].
The 3e (Evidence, Expertise, Exchange) Initiative is a
multinational collaboration aimed at promoting evidence-
based practice in rheumatology by developing practical
recommendations that address important clinical prob-
lems [57]. The objective of the 2010 3e Initiative was to
develop recommendations for the use of pharmacother-
apy in the management of pain in patients with IA by
integrating systematically generated evidence with the ex-
pertise of a broad panel of international rheumatologists.
Methods
A total of 453 rheumatologists from 17 countries partici-
pated in the 2010 3e Initiative. Participating countries from
Europe, Canada, South America and Australasia were
represented by 15 scientific committees. The members
of each of the national scientific committees formed the
panel of experts that attended the multinational meetings.
In addition, the bibliographic team comprised 10 multina-
tional fellows (S.L.W., A.N.C., K.A., M.E., G.H., J.L.M.,
H.R., S.R., B.L.R. and I.H.T.), 6 mentors (D.A., C.B.,
R.B., C.J.E., R.L. and U.M.-L.) and the scientific chair
(D.vdH.).
At the first international meeting, 10 clinically relevant
questions regarding pain management in IA were formu-
lated and selected via a modified Delphi voting process by
the panel of 89 expert rheumatologists representing all
17 countries. In order to develop a set of recommenda-
tions that was sufficiently focused to be of practical value
to clinicians, non-pharmacological interventions were not
considered in the current project. IA was defined as com-
prising RA, PsA, AS and SpA.
The multinational fellows undertook a systematic litera-
ture review (SLR) for each of the clinical questions.
One clinical question regarding the importance of
comorbidities was divided into two parts in order to
allow a more manageable literature search; this resulted
in a total of 11 questions for which an SLR was performed
and recommendations were produced. A comprehensive
search strategy was formulated for each question in con-
junction with an experienced librarian and, where appro-
priate, the search terms were standardized for each of the
SLRs. A search was conducted in MEDLINE, EMBASE
and the Cochrane Central Register of Controlled Trials
(CENTRAL), and hand searches were performed of ab-
stracts presented at the ACR and European League
Against Rheumatism (EULAR) scientific meetings in 2008
and 2009. The titles and abstracts of all citations identified
by the searches were screened, and potentially relevant
articles were reviewed in full text for inclusion according to
predetermined inclusion and exclusion criteria. Included
articles were restricted to those published in languages
in which at least one member of the bibliographic group
was fluent. All trials of interventions were assessed for risk
of bias according to the methods recommended by the
Cochrane Collaboration [8]. Details and results of the SLR
for each question will be published separately.
Following presentation of the SLR results, each of the
15 national scientific committees produced recommenda-
tions regarding the 11 clinical questions and a provisional
algorithm for the pharmacological management of pain in
IA. At the final international meeting, the members of each
of the scientific committees merged the national recom-
mendations into 11 final recommendations and a treat-
ment algorithm via a process of discussion and a
modified Delphi vote.
The participating rheumatologists quantified their
agreement with each recommendation and the potential
impact of each recommendation on their clinical practice.
The level of evidence for each component of the recom-
mendations was appraised, and each recommendation
was graded in accordance with the Oxford Centre for
Evidence-based Medicine Levels of Evidence [9]. Where
there was ambiguity regarding the appropriate grade or
level of evidence, a lower grade or level was chosen.
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In total, 49 242 references were identified, from which
167 studies were included in the SLRs. The 11 final multi-
national recommendations are listed in Table 1 with the
levels of evidence and grade of recommendation. The
level of agreement by the participants with the recommen-
dations ranged from 8.5 to 9.3 (mean 8.9) on a 110 point
scale, where 10 represents full agreement (Table 1).
Recommendation 1
In patients with IA, pain should be measured routinely
using one of the following validated scales: VAS, NRS
or VRS; in addition, consider multi-dimensional meas-
ures or site-specific tools as needed.
Fifty-one studies were identified that evaluated a total of
20 tools that have been used in the setting of IA (predom-
inantly RA) to measure patient-reported pain. The visual
analogue scale (VAS) for overall pain intensity is currently
the best evaluated pain measure in RA, but the related
single-item measures, numerical rating scale (NRS) and
verbal rating scale (VRS) demonstrated comparable clini-
metric properties [10].
There was a consensus among the experts that meas-
urement of pain is an important component of routine clin-
ical care in patients with IA. Pain scales that measure
overall pain (such as VAS, NRS or VRS) were felt to be
most useful. It was recognized that multi-dimensional
tools, which measure different characteristics of the phe-
nomenon of pain, and tools limited to specific anatomical
sites are also useful in certain clinical or research situ-
ations, but are not required in routine practice.
Recommendation 2
Paracetamol is recommended for the treatment of
persistent pain in patients with IA.
Data from 12 short-term randomized controlled trials
(RCTs) at high risk of bias provided weak evidence for a
benefit of paracetamol over placebo and an additive
benefit of paracetamol in combination with NSAIDs [11].
Heterogeneity among the trials prevented meta-analysis.
No important safety signals were identified in subjects
treated with standard doses of paracetamol.
There was consensus among the experts that paraceta-
mol is generally a safe and effective analgesic in IA, both
alone and in combination with other pain pharmacothera-
pies. It was recognized that there is variation between
countries in the maximum recommended dose and that
clinicians should follow local dosing guidelines. No evi-
dence exists regarding the preferred formulation or
dosing interval.
Recommendation 3
Systemic glucocorticoids are not recommen-
ded for the routine management of pain in patients
with IA in the absence of signs and symptoms of
inflammation.
Despite a comprehensive search strategy, no studies
were found that addressed the role of systemic gluco-
corticoids as an analgesic therapy in IA [12]. While a
rationale exists for a potential analgesic effect of gluco-
corticoids [13], there are as yet no clinical data in this
setting to support such a notion. The adverse effects of
long-term glucocorticoid use are well recognized [14].
Intra-articular glucocorticoids were not considered for
this recommendation as they are generally considered to
be useful in the management of localized inflammation in
IA. While the anti-inflammatory properties of systemic
glucocorticoids are recognized to play an important role
in the management of IA, the experts strongly agreed that
there is no role for steroids in the treatment of IA pain
when inflammation is adequately suppressed.
Recommendation 4
In the treatment of pain in IA, tricyclic anti-
depressants and neuromodulators may be considered
for use as adjuvant treatment; muscle relaxants and
benzodiazepines cannot be recommended.
There was conflicting evidence regarding the efficacy of
tricyclic anti-depressants (TCAs) as analgesics in eight
RCTs in patients with RA and a single trial in AS. The
majority of the trials were at high risk of bias. Adverse
events (AEs) were more common in those treated with
TCAs vs placebo, but there was no increase in the
number of withdrawals due to AEs [15]. The experts
agreed that while the evidence regarding TCAs as anal-
gesic agents is unclear, there may be a role for this class
of medications in selected patients. There is insufficient
evidence regarding the role of newer anti-depressants
in patients with IA to warrant a recommendation at
this time.
Despite the use of a broad definition of neuromodula-
tors as ‘substances that alter nerve transmission’ in the
initial literature search, data regarding the use of these
drugs in this population was scarce. Pooled analysis of
two short-term trials of the centrally acting non-opioid an-
algesic nefopam in RA demonstrated significant reduction
in pain at 2 weeks compared with placebo, but the risk of
AEs was also significantly increased [1618]. One study of
topical capsaicin for knee pain in RA suggested a benefit
at 2 weeks, although local skin irritation was a frequent
occurrence [19]. There are no data regarding the use of
anti-convulsants as analgesics in IA, although both preg-
abalin and gabapentin have been shown to reduce pain in
patients with FM syndrome [2022]. The experts agreed
that although the evidence regarding neuromodulators in
IA is very limited, these drugs, including nefopam and
topical capsaicin, and potentially the newer anticon-
vulsants, may be considered as adjuvant therapies in
individual patients.
Benzodiazepines are hypnotic and anxiolytic agents that
have some muscle relaxant properties [23]. In six
short-term RCTs, no improvement in pain outcomes
was seen in those taking muscle relaxants compared
with placebo, and both benzodiazepines [24] and
non-benzodiazepine muscle relaxants [25] were asso-
ciated with a significant increase in the risk of AEs [26].
Given this lack of evidence for benefit and the potential
for harm (including addiction), the experts recommended
against the use of benzodiazepines as analgesics. The
paucity of evidence regarding non-benzodiazepine
muscle relaxants prevented a specific recommendation
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regarding these drugs, although it was recognized
that most clinicians would not regard them as analgesic
agents.
Recommendation 5
Weak opioids may be used for short-term treatment of
pain in patients with IA when other therapies have
failed or are contraindicated; long-term use may be
considered and should be regularly reviewed. Strong
opioids should only be used in exceptional cases.
While clinicians and regulatory bodies commonly
classify opioids as being ‘weak’ or ‘strong’, no consensus
classification system exists, and there is no clear
pharmacological distinction at the receptor level between
drugs to which either of these labels are commonly
TABLE 1 Multinational recommendations on pain management by pharmacotherapy in IA
Recommendation (with level of evidence and grade of recommendation)
Agreement,
mean (S.D.)
(1) In patients with IA, pain should be measured routinely using one of the following validated
scales: VAS, NRS or VRS; in addition, consider multi-dimensional measures or site-specific
tools as needed.
8.6 (1.8)
Level of evidence: NA; grade of recommendation: NA
(2) Paracetamol is recommended for the treatment of persistent pain in patients with IA. 8.8 (1.6)
RA: Level of evidence: 2ba; grade of recommendation: C
Other IA: level of evidence 5; grade of recommendation: D
(3) Systemic glucocorticoids are not recommended for the routine management of pain in
patients with IA in the absence of signs and symptoms of inflammation.
9.2 (1.6)
Level of evidence: 5; grade of recommendation: D
(4) In the treatment of pain in IA, TCAs and neuromodulators may be considered for use as
adjuvant treatment;* muscle relaxants and benzodiazepines cannot be recommended.**
9.2 (1.6)
*Level of evidence: 5; grade of recommendation: D
**Level of evidence: 2ba (RA), 5 (other IA); grade of recommendation: C (RA), D (other IA)
(5) Weak opioids may be used for short-term treatment of pain in patients with IA when other
therapies have failed or are contraindicated;* long-term use may be considered and should be
regularly reviewed.** Strong opioids should only be used in exceptional cases.**
8.5 (1.5)
*Level of evidence: 2ba (RA), 5 (other IA); grade of recommendation: D (RA), D (other IA)
**Level of evidence: 5; grade of recommendation: D
(6) In patients with an inadequate response to paracetamol or NSAID monotherapy, adding a drug
with a different mode of action could be considered; combination of two or more NSAIDs
should not be used.
9.2 (0.9)
Level of evidence: 5; grade of recommendation: D
(7) NSAIDs should be used at the lowest effective dose, either continuously or on demand,
according to clinical circumstances.
9.1 (1.4)
Level of evidence: 5; grade of recommendation: D
(8) Existing guidance regarding the safety of pain pharmacotherapies during pre-conception,
pregnancy and lactation should be applied.
8.6 (1.6)
Level of evidence: 5; grade of recommendation: D
(9) In the management of patients with IA, MTX can be used safely in combination with standard
doses of paracetamol and/or NSAIDs (excluding anti-inflammatory doses of aspirin).
9.3 (1.0)
RA and NSAIDs: level of evidence: 4; grade of recommendation: C
Other IA and NSAIDs: level of evidence: 5; grade of recommendation: D
All IA and paracetamol: level of evidence: 5; grade of recommendation: D
(10) In patients with GI comorbidities paracetamol should be considered first;* non-selective
NSAIDs in combination with PPI, or COX-2 selective inhibitors ± PPI, may be used with
caution.** In the presence of liver disease standard precautions for use of NSAIDs and
other analgesics should be applied.*
8.8 (1.4)
*Level of evidence: 5; grade of recommendation: D
**Level of evidence: 3 (RA), 5 (other IA); grade of recommendation: C (RA), D (other IA)
(11) In patients with IA and pre-existing hypertension,* CV* or renal disease,** paracetamol should
be used first; NSAIDs including COX-2 selective inhibitors should be used with caution.
8.8 (1.2)
*Level of evidence: 2a (RA), 5 (other IA); grade of recommendation: C (RA), D (other IA)
**Level of evidence: 5; grade of recommendation: D
Level of evidence and grade of recommendation according to the Oxford Centre for Evidence-based Medicine Levels of
Evidence (http://www.cebm.net/index.aspx?o=1025). aLevel 1a evidence [Systematic Review with troublesome (and statistic-
ally significant) heterogeneity of RCTs] was downgraded to Level 2b to indicate that most included RCTs were at high risk of
bias and the results may not apply to IA patients taking anti-rheumatic medication based upon current standards. Agreement
relates to the entire statement and was voted on a scale from 1 to 10 (fully disagree to fully agree) by the 76 rheumatologists
attending the 3e Multinational Closing Meeting (Brussels, 1920 November 2010). These attendees were members of the 15
national scientific committees involved in 3e. NA: not available.
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applied [27, 28]. Eleven RCTs of opioids in RA were iden-
tified: 10 studied opioids that were considered to be
weak, including codeine, tilidine, pentazocine, dextropro-
poxyphene and tramadol [29].
Meta-analysis of pain outcomes up to 6 weeks from
three placebo-controlled studies found treatment with
weak oral opioids resulted in superior patient-reported
global impression of clinical change [3032]. AEs were
significantly more frequent in opioid-treated patients,
and after adjustment for AEs there was no difference be-
tween opioids and placebo in net efficacy [29, 33].
Although the experts agreed that short-term use of opi-
oids in some patients with IA may have an acceptable
riskbenefit profile, caution was advised for long-term
use. Given the lack of evidence regarding the use of
strong opioids in IA pain and the significant potential for
harm, the experts recommended that they should be used
only where other treatments have failed, and should be
supervised by a clinician experienced in the prescription
of strong opioids.
Recommendation 6
In patients with an inadequate response to paraceta-
mol or NSAID monotherapy, adding a drug with a
different mode of action could be considered; combin-
ation of two or more NSAIDs should not be used.
The use of different analgesic drugs in combination is
often recommended to permit the use of lower doses of
each analgesic by targeting different pain pathways sim-
ultaneously [34]. Twenty-three trials were identified that
compared combination analgesic therapy with monother-
apy in IA: all were published before 1994 and all were at
high risk of bias [35]. There were no trials in IAs other than
RA. Heterogeneity of the included trials precluded
meta-analysis.
Despite the inconclusive evidence, the experts felt
that in patients for whom analgesic monotherapy was in-
sufficient, clinicians could choose to trial an alternative
drug from a different class, or a combination of drugs
with different modes of action, and that the decision
should be made with regard to the individual patient. The
use of more than one drug with the same mode of action, in
particular NSAIDs and opioids, is likely to disproportion-
ately increase the risk of AEs and should be avoided.
Recommendation 7
NSAIDs should be used at the lowest effective dose,
either continuously or on demand, according to clin-
ical circumstances.
It is not known whether there is a difference in the
riskbenefit profile of NSAIDs when used as continuous
therapy rather than on demand. Only one relevant RCT
was identified (in individuals with AS), in which no signifi-
cant difference was found between the intervention
groups for pain measures or AEs [36, 37].
In the absence of strong evidence regarding the optimal
method of NSAID use, the experts believed that NSAID
therapy should be tailored to the individual patient’s clin-
ical circumstances. Given the risk of serious AEs, the ex-
perts considered it axiomatic that the lowest effective
dose and briefest possible course of NSAID therapy
should be sought for all patients in whom these drugs
are used.
Recommendation 8
Existing guidance regarding the safety of pain phar-
macotherapies during pre-conception, pregnancy and
lactation should be applied.
There are few data regarding the safety of analgesics
during pregnancy and lactation in women with IA [38].
Pre-conception was excluded from the review, as it
significantly complicated the review process.
There was extensive debate among the experts regard-
ing the suitability of specific recommendations for this
question. A close vote favoured a general recommenda-
tion over specific recommendations regarding individual
drug classes. While the experts were mostly of the opinion
that paracetamol is generally safe in pregnant women and
that NSAIDs may be used with caution before the third
trimester, the group wished to emphasize that decisions
regarding pharmacotherapy in pregnant and lactating
women should be made jointly by the rheumatologist, ob-
stetrician and patient. At present there is no evidence to
suggest that women with IA are a sufficiently unique sub-
group to warrant recommendations that deviate from
existing guidelines regarding the use of drugs in preg-
nancy. As such, existing guidance regarding these medi-
cations should be applied equally to women with IA as to
the general population.
Recommendation 9
In the management of patients with IA, MTX can
be used safely in combination with standard doses
of paracetamol and/or NSAIDs (excluding anti-
inflammatory doses of aspirin).
A systematic review of RCTs and non-randomized stu-
dies regarding the safety of using NSAIDs and/or para-
cetamol with MTX in IA identified 17 studies, all in
patients with RA [39]. Most of the included studies were
of a low to moderate quality. No studies were identified for
the combination of MTX and paracetamol, but the experts
considered this combination to be generally safe. There
was no effect of concurrent NSAID use on the incidence of
MTX-related AEs or the rate of MTX withdrawal [4045].
The use of MTX in addition to anti-inflammatory doses
of aspirin has been reported to have an adverse effect on
liver [46] and renal [47] function. The evidence regarding
low-dose aspirin for the prevention of atherothrombotic
disease is less clear, although pharmacokinetic data sug-
gest that aspirin at daily doses of 5650 mg has different
pharmacokinetic properties and is more likely to increase
risk in combination with MTX [39, 4850].
Recommendation 10
In patients with gastrointestinal comorbidities, para-
cetamol should be considered first; non-selective
NSAIDs in combination with PPI, or COX-2 selective
inhibitors ± PPI, may be used with caution. In the pres-
ence of liver disease, standard precautions for use of
NSAIDs and other analgesics should be applied.
Data regarding the safety and efficacy of analgesic
drugs in patients with IA and existing or prior gastrointes-
tinal (GI) or hepatic morbidity could be identified for
1420 www.rheumatology.oxfordjournals.org












NSAIDs only [51]. In RA patients treated with NSAIDs
there is an increased risk of GI events in individuals with
prior uncomplicated GI events or a history of upper GI
symptoms [52]. A meta-analysis of five RCTs involving
patients with RA or OA who were receiving NSAIDs also
found an increased risk of upper GI events in those with a
history of gastro-duodenal ulceration [53].
The experts agreed that paracetamol should be con-
sidered as the first-line analgesic in this setting due to
the risk of recurrent GI events. Caution should also be
exercised in patients with risk factors for significant GI
events, including patients without documented prior
events, although the magnitude of any increase in risk in
these patients cannot be estimated from the literature.
Where NSAIDs are required, the experts recommended
that either non-selective NSAIDs in combination with
proton-pump inhibitors (PPI), or COX-2 selective inhibitors
(alone or in combination with PPI) may be used with close
surveillance for AEs.
There is little evidence regarding the efficacy and safety
of analgesic drugs in patients with IA and co-morbid hep-
atic disease [51] The experts believed that as the risk
associated with the use of analgesics such as paraceta-
mol, NSAIDs and opioids in patients with IA and liver dis-
ease is likely to be similar to that seen in other patients
with hepatic dysfunction, prescribers should exercise a
similar level of caution when using these drugs in IA pa-
tients as in other populations.
Recommendation 11
In patients with IA and pre-existing hypertension, car-
diovascular or renal disease, paracetamol should be
used first; NSAIDs including COX-2 selective inhibitors
should be used with caution.
Few studies were found that directly assessed the risk
of analgesic drugs in patients with IA and co-morbid renal
or cardiovascular (CV) disease [54]. Data from a large RCT
comparing diclofenac and etoricoxib in a mixed popula-
tion of OA and RA were available for patients with
pre-existing CV disease [55]. Subjects with CV disease
who were treated with either etoricoxib or diclofenac
had a 3-fold increase in the risk of thrombotic events
compared with those without CV disease. No data was
available regarding other IAs and there were no studies
that directly assessed the influence of renal disease on the
riskbenefit profile of analgesics in IA.
The potential for CV events, renal dysfunction and
hypertension in individuals treated with NSAIDs is well
recognized [5658], although the magnitude of this risk
in patients with both IA and renal or CV disease remains
unclear. Despite preliminary evidence that paracetamol
might increase blood pressure in patients with existing
coronary artery disease [59], there is as yet no convincing
epidemiological evidence to suggest that paracetamol
contributes to increased vascular risk in a manner com-
parable with NSAIDs. Therefore, the experts agreed that
the most reasonable approach would be to use paraceta-
mol as the primary analgesic in this setting. There was
insufficient data to make specific recommendations
about other analgesic drugs.
Algorithm
Based on the recommendations that were developed, the
experts proposed an algorithm for the management of
pain by pharmacotherapy in patients with IA (Fig. 1). The
therapeutic algorithm is predicated on the assumption
that the clinician’s first goal is to optimally control inflam-
mation with DMARDs according to current practice
(including the use of biologic DMARDs and glucocortic-
oids), although it is recognized that response to DMARDs
is often delayed, may vary over time, and that complete
suppression of inflammation is not always achievable.
The use of NSAIDs, paracetamol and weak opioids in
the algorithm reflects the recommendations above. Due to
concerns regarding the riskbenefit profile of strong opi-
oids, these drugs do not form part of the main algorithm,
but may be used with caution under exceptional circum-
stances, as described in Recommendation 5.
As discussed in Recommendation 4, TCAs and neuro-
modulators are not recommended as analgesic options in
isolation, but may be considered as adjuvants in a com-
prehensive analgesic strategy, at any point in the pro-
posed algorithm. Evidence exists for the use of TCAs
only in this population. The experts recognized that
data now exist regarding the efficacy of newer anti-
depressants (such as duloxetine and milnacipran) and
the neuromodulators (pregabalin and gabapentin) in
FMS, and that while there are no data regarding the use
of these drugs in IA, some clinicians may choose to trial
them as adjuvants where central sensitization is thought
to be contributing to persistent pain [20, 22, 6062].
Importantly, any analgesic strategy must be tailored to
the individual patient, and must reflect the relative risks
and benefits in the individual circumstances, as well as the
patient’s values. The experts included several points to
consider at all stages of the therapeutic algorithm, includ-
ing the type of IA, comorbidities and the preferences of
the individual patient. The pain phenotype (e.g. peripheral
nociception from joint damage, vs diffuse pain associated
with central sensitization) was thought to be important in
tailoring treatment, and should be assessed at each
clinical encounter, in addition to an assessment for the
presence of residual (treatable) inflammation.
Impact of recommendations
The recommendations are in accordance with the current
clinical practice of the majority of the participating
rheumatologists. The proportion of rheumatologists who
indicated they would change their practice according to
each recommendation is listed in Table 2. Notably, the
measurement of pain, the use of anti-depressants,
muscle relaxants and neuromodulators, and the final al-
gorithm resulted in modification of clinical practice in
16.730% of the rheumatologists.
Discussion
The 2010 3e Initiative developed 11 recommendations
and an algorithm for the management of pain by pharma-
cotherapy in IA. The recommendations, which were
www.rheumatology.oxfordjournals.org 1421












developed to address clinical questions that are important
to practicing rheumatologists, are informed by the current
evidence base and are supported by a large panel of inter-
national rheumatologists.
This process has a number of strengths. First, the
breadth of participation in the 3e Initiative ensures its
relevance and promotes the implementation of the
recommendations into rheumatology practice worldwide.
There was a high level of agreement with the final recom-
mendations, and one in five of the expert rheumatologists
reported that the algorithm would change their practice.
Second, a rigorous approach was taken to both the sys-
tematic appraisal of the evidence base, including a highly
sensitive search strategy, and the formal voting process
FIG. 1 Algorithm for pain management by pharmacotherapy in IA. The central column of the algorithm contains rec-
ommendations for the choice of medications for individuals with IA who experience pain despite optimal management
of inflammation. It is recommended that clinicians first select an option from the top row, and move sequentially to
lower rows when the options in each row are either ineffective or contraindicated. Adjuvant options may be
introduced at any point in the algorithm, where appropriate. Each decision within the algorithm should be made
with regard to the individual patient, including the points to consider in the left column. Level of evidence: 5. Grade of
recommendation: D. Agreement 8.4/10.






















• Type of pain
• Addictive 
potential
Therapeutic algorithm Adjuvant therapeutic optionsPoints to consider
Only in exceptional cases
strong opioids ± paracetamol ± NSAID
Neuro -
modulators
TABLE 2 Impact of recommendations on the practice of rheumatologists in the 3e Initiative










I do not want to
apply this
recommendation
in my practice, %
1. Measurement of pain 30.0 63.3 6.7
2. Paracetamol 3.3 85.0 11.7
3. Glucocorticoids 1.7 93.3 5.0
4. Anti-depressants, muscle relaxants, neuromodulators 16.7 70.0 13.3
5. Opioids 8.3 85.0 6.7
6. Combination therapy 1.7 98.3 0.0
7. Continuous vs on-demand NSAIDs 5.0 91.7 3.3
8. Pregnancy and lactation 1.7 91.7 6.7
9. MTX + NSAIDs or paracetamol 1.7 96.7 1.7
10. GI and hepatic comorbidity 3.3 91.7 5.0
11. CV and renal comorbidity 6.8 86.4 6.8
12. Algorithm 20.0 75.0 5.0
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for the development of the clinical questions and final
recommendations.
There was relatively little evidence available for many of
the questions in this 3e Initiative, particularly regarding IAs
other than RA. Many of the included studies were per-
formed in an era that pre-dates the current practice of
early intensive therapy, and the use of novel DMARDs,
including the biologic drugs, which may limit applicability
to patients in the modern era. This resulted in generally
low Oxford levels of evidence within the recommen-
dations, although we took a conservative approach to
appraisal and chose to downgrade by one level where
there was heterogeneity among the included studies.
Nonetheless, the recommendations represent the integra-
tion of the best available evidence and multinational
clinical expertise, and as such remain a valuable tool for
rheumatologists in the clinic. Moreover, our findings high-
light the need for further well-designed clinical trials of
analgesic drugs in patients with a variety of inflammatory
arthropathies, taking into account current immunomodu-
latory strategies, novel analgesic drugs and modern
understanding of the neurobiology of pain.
In summary, 11 multinational recommendations and an
algorithm for pain management by pharmacotherapy in IA
were developed. They are evidence based and supported
by a large panel of rheumatologists from 17 countries,
thus enhancing their utility in clinical practice.
Rheumatology key messages
. Good pain management is a high priority for indi-
viduals with IA.
. Recommendations for the pharmacological man-
agement of pain integrate the best available evi-
dence and international expertise.
. The systematic literature reviews highlight the large
research agenda for pain management in IA.
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